11
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Rates and Factors Associated With Documentation of Diagnostic Codes for Long COVID in the National Veterans Affairs Health Care System

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Key Points

          Question

          What are the rates, clinical settings, and factors associated with documentation of care related to COVID-19 at 3 or more months after acute infection?

          Findings

          In this cohort study of 198 601 persons with a positive SARS-CoV-2 test, COVID-19 care was documented in 13.5% of individuals 3 or more months after infection during a mean follow-up of 13.5 months and was documented more commonly in older persons, those with higher comorbidity burden, those with more severe acute COVID-19 presentation, and those who were unvaccinated at the time of infection.

          Meaning

          These findings provide guidance for health care systems to develop systematic approaches to the evaluation and management of patients who may be experiencing long COVID.

          Abstract

          This cohort study examines the rates, clinical setting, and factors associated with documented receipt of COVID-19–related care 3 or more months after acute infection among veterans treated in the US Department of Veterans Affairs health care system.

          Abstract

          Importance

          Some persons infected with SARS-CoV-2 experience symptoms or impairments many months after acute infection.

          Objectives

          To determine the rates, clinical setting, and factors associated with documented receipt of COVID-19–related care 3 or more months after acute infection.

          Design, Setting, and Participants

          This retrospective cohort study used data from the US Department of Veterans Affairs health care system. Participants included persons with a positive SARS-CoV-2 test between February 1, 2020, and April 30, 2021, who were still alive 3 months after infection and did not have evidence of reinfection. Data analysis was performed from February 2020 to December 2021.

          Exposures

          Positive SARS-CoV-2 test.

          Main Outcomes and Measures

          Rates and factors associated with documentation of COVID-19–related International Statistical Classification of Diseases and Related Health Problems, Tenth Revision codes (U07.1, Z86.16, U09.9, and J12.82) 3 or more months after acute infection (hereafter, long-COVID care), with follow-up extending to December 31, 2021.

          Results

          Among 198 601 SARS-CoV-2–positive persons included in the study, the mean (SD) age was 60.4 (17.7) years, 176 942 individuals (89.1%) were male, 133 924 (67.4%) were White, 44 733 (22.5%) were Black, and 19 735 (9.9%) were Hispanic. During a mean (SD) follow-up of 13.5 (3.6) months, long-COVID care was documented in a wide variety of clinics, most commonly primary care and general internal medicine (18 634 of 56 310 encounters [33.1%]), pulmonary (7360 of 56 310 encounters [13.1%]), and geriatrics (5454 of 56 310 encounters [9.7%]). Long-COVID care was documented in 26 745 cohort members (13.5%), with great variability across geographical regions (range, 10.8%-18.1%) and medical centers (range, 3.0%-41.0%). Factors significantly associated with documented long-COVID care included older age, Black or American Indian/Alaska Native race, Hispanic ethnicity, geographical region, high Charlson Comorbidity Index score, having documented symptoms at the time of acute infection (adjusted odds ratio [AOR], 1.71; 95% CI, 1.65-1.78) and requiring hospitalization (AOR, 2.60; 95% CI, 2.51-2.69) or mechanical ventilation (AOR, 2.46; 95% CI, 2.26-2.69). Patients who were fully vaccinated at the time of infection were less likely to receive long-COVID care (AOR, 0.78; 95% CI, 0.68-0.90).

          Conclusions and Relevance

          Long-COVID care was documented in a variety of clinical settings, with great variability across regions and medical centers and was documented more commonly in older persons, those with higher comorbidity burden, those with more severe acute COVID-19 presentation and those who were unvaccinated at the time of infection. These findings provide support and guidance for health care systems to develop systematic approaches to the evaluation and management of patients who may be experiencing long COVID.

          Related collections

          Most cited references32

          • Record: found
          • Abstract: found
          • Article: not found

          6-month consequences of COVID-19 in patients discharged from hospital: a cohort study

          Background The long-term health consequences of COVID-19 remain largely unclear. The aim of this study was to describe the long-term health consequences of patients with COVID-19 who have been discharged from hospital and investigate the associated risk factors, in particular disease severity. Methods We did an ambidirectional cohort study of patients with confirmed COVID-19 who had been discharged from Jin Yin-tan Hospital (Wuhan, China) between Jan 7, 2020, and May 29, 2020. Patients who died before follow-up, patients for whom follow-up would be difficult because of psychotic disorders, dementia, or re-admission to hospital, those who were unable to move freely due to concomitant osteoarthropathy or immobile before or after discharge due to diseases such as stroke or pulmonary embolism, those who declined to participate, those who could not be contacted, and those living outside of Wuhan or in nursing or welfare homes were all excluded. All patients were interviewed with a series of questionnaires for evaluation of symptoms and health-related quality of life, underwent physical examinations and a 6-min walking test, and received blood tests. A stratified sampling procedure was used to sample patients according to their highest seven-category scale during their hospital stay as 3, 4, and 5–6, to receive pulmonary function test, high resolution CT of the chest, and ultrasonography. Enrolled patients who had participated in the Lopinavir Trial for Suppression of SARS-CoV-2 in China received severe acute respiratory syndrome coronavirus 2 antibody tests. Multivariable adjusted linear or logistic regression models were used to evaluate the association between disease severity and long-term health consequences. Findings In total, 1733 of 2469 discharged patients with COVID-19 were enrolled after 736 were excluded. Patients had a median age of 57·0 (IQR 47·0–65·0) years and 897 (52%) were men. The follow-up study was done from June 16, to Sept 3, 2020, and the median follow-up time after symptom onset was 186·0 (175·0–199·0) days. Fatigue or muscle weakness (63%, 1038 of 1655) and sleep difficulties (26%, 437 of 1655) were the most common symptoms. Anxiety or depression was reported among 23% (367 of 1617) of patients. The proportions of median 6-min walking distance less than the lower limit of the normal range were 24% for those at severity scale 3, 22% for severity scale 4, and 29% for severity scale 5–6. The corresponding proportions of patients with diffusion impairment were 22% for severity scale 3, 29% for scale 4, and 56% for scale 5–6, and median CT scores were 3·0 (IQR 2·0–5·0) for severity scale 3, 4·0 (3·0–5·0) for scale 4, and 5·0 (4·0–6·0) for scale 5–6. After multivariable adjustment, patients showed an odds ratio (OR) 1·61 (95% CI 0·80–3·25) for scale 4 versus scale 3 and 4·60 (1·85–11·48) for scale 5–6 versus scale 3 for diffusion impairment; OR 0·88 (0·66–1·17) for scale 4 versus scale 3 and OR 1·77 (1·05–2·97) for scale 5–6 versus scale 3 for anxiety or depression, and OR 0·74 (0·58–0·96) for scale 4 versus scale 3 and 2·69 (1·46–4·96) for scale 5–6 versus scale 3 for fatigue or muscle weakness. Of 94 patients with blood antibodies tested at follow-up, the seropositivity (96·2% vs 58·5%) and median titres (19·0 vs 10·0) of the neutralising antibodies were significantly lower compared with at the acute phase. 107 of 822 participants without acute kidney injury and with estimated glomerular filtration rate (eGFR) 90 mL/min per 1·73 m2 or more at acute phase had eGFR less than 90 mL/min per 1·73 m2 at follow-up. Interpretation At 6 months after acute infection, COVID-19 survivors were mainly troubled with fatigue or muscle weakness, sleep difficulties, and anxiety or depression. Patients who were more severely ill during their hospital stay had more severe impaired pulmonary diffusion capacities and abnormal chest imaging manifestations, and are the main target population for intervention of long-term recovery. Funding National Natural Science Foundation of China, Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences, National Key Research and Development Program of China, Major Projects of National Science and Technology on New Drug Creation and Development of Pulmonary Tuberculosis, and Peking Union Medical College Foundation.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            Persistent Symptoms in Patients After Acute COVID-19

            This case series describes COVID-19 symptoms persisting a mean of 60 days after onset among Italian patients previously discharged from COVID-19 hospitalization.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Post-acute COVID-19 syndrome

              Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen responsible for the coronavirus disease 2019 (COVID-19) pandemic, which has resulted in global healthcare crises and strained health resources. As the population of patients recovering from COVID-19 grows, it is paramount to establish an understanding of the healthcare issues surrounding them. COVID-19 is now recognized as a multi-organ disease with a broad spectrum of manifestations. Similarly to post-acute viral syndromes described in survivors of other virulent coronavirus epidemics, there are increasing reports of persistent and prolonged effects after acute COVID-19. Patient advocacy groups, many members of which identify themselves as long haulers, have helped contribute to the recognition of post-acute COVID-19, a syndrome characterized by persistent symptoms and/or delayed or long-term complications beyond 4 weeks from the onset of symptoms. Here, we provide a comprehensive review of the current literature on post-acute COVID-19, its pathophysiology and its organ-specific sequelae. Finally, we discuss relevant considerations for the multidisciplinary care of COVID-19 survivors and propose a framework for the identification of those at high risk for post-acute COVID-19 and their coordinated management through dedicated COVID-19 clinics.
                Bookmark

                Author and article information

                Journal
                JAMA Netw Open
                JAMA Netw Open
                JAMA Network Open
                American Medical Association
                2574-3805
                29 July 2022
                July 2022
                29 July 2022
                : 5
                : 7
                : e2224359
                Affiliations
                [1 ]Health Services Research and Development, Center of Innovation, Veterans Affairs Puget Sound Healthcare System, Seattle, Washington
                [2 ]Division of Gastroenterology, Department of Medicine, University of Washington, Seattle
                [3 ]Seattle Epidemiologic Research and Information Center, Veterans Affairs Puget Sound Health Care System, Seattle, Washington
                [4 ]Department of Veterans Affairs, Population Health, Palo Alto Healthcare System, Palo Alto, California
                [5 ]Center of Innovation to Improve Veteran Involvement in Care, VA Portland Healthcare System, Portland, Oregon
                [6 ]Nephrology Section, Veterans Affairs Puget Sound Healthcare System, Seattle, Washington
                [7 ]Division of Nephrology, University of Washington, Seattle
                [8 ]Department of Psychiatry, University of Michigan Medical School, Ann Arbor
                [9 ]General Internal Medicine, Veterans Affairs Puget Sound Healthcare System, Seattle, Washington
                [10 ]Division of General Internal Medicine, University of Washington, Seattle
                [11 ]Center of Innovation to Accelerate Discovery and Practice Transformation, Durham Veterans Affairs Health Care System, Durham, North Carolina
                [12 ]Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina
                [13 ]Duke-Margolis Center for Health Policy, Duke University School of Medicine, Durham, North Carolina
                [14 ]Division of General Internal Medicine, Duke University School of Medicine, Durham, North Carolina
                [15 ]Durham Veterans Affairs Geriatric Research Education and Clinical Center, Durham Veterans Affairs Medical Center, Durham, North Carolina
                [16 ]Department of Medicine, Duke University, Durham, North Carolina
                [17 ]Center for Clinical Management Research, VA Ann Arbor Health System, Ann Arbor, Michigan
                [18 ]Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor
                [19 ]Health Management and Policy, School of Social and Behavioral Health Sciences, College of Public Health and Human Sciences, Corvallis, Oregon
                [20 ]Health Data and Informatics Program, Center for Genome Research and Biocomputing, Oregon State University, Corvallis
                Author notes
                Article Information
                Accepted for Publication: June 13, 2022.
                Published: July 29, 2022. doi:10.1001/jamanetworkopen.2022.24359
                Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2022 Ioannou GN et al. JAMA Network Open.
                Corresponding Author: George N. Ioannou, BMBCh, MS, Health Services Research and Development, Center of Innovation, Veterans Affairs Puget Sound Healthcare System, 1660 S Columbian Way, Seattle, WA 98108 ( georgei@ 123456medicine.washington.edu ).
                Author Contributions: Dr Ioannou and Mr Baraff had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
                Concept and design: Ioannou, Maciejewski, Bowling, Iwashyna, Hynes.
                Acquisition, analysis, or interpretation of data: Ioannou, Baraff, Fox, Shahoumian, Hickok, O’Hare, Bohnert, Boyko, Bowling, Viglianti, Iwashyna, Hynes.
                Drafting of the manuscript: Ioannou.
                Critical revision of the manuscript for important intellectual content: All authors.
                Statistical analysis: Ioannou, Baraff, Shahoumian, Hickok.
                Obtained funding: Ioannou, O’Hare, Bohnert, Boyko, Iwashyna, Hynes.
                Administrative, technical, or material support: Bohnert, Maciejewski, Bowling, Hynes.
                Conflict of Interest Disclosures: Dr Ioannou reported receiving grants from the Department of Veterans Affairs (VA) during the conduct of the study. Dr Hickok reported receiving grants from the VA during the conduct of the study. Dr O’Hare reported receiving grants from VA Puget Sound Health and the National Institute of Diabetes and Digestive and Kidney Disease, and personal fees from American Society of Nephrology, Devenir Foundation, Hammersmith Hospital, and Kaiser Permanente Northern California outside the submitted work. Dr Boyko reported receiving grants from the VA during the conduct of the study. Dr Maciejewski reported owning Amgen stock because of his spouse’s employment. Dr Bowling reported receiving grants from VA Health Services Research and Development Service (HSR&D) during the conduct of the study. Dr Hynes reported grants from US VA during the conduct of the study. No other disclosures were reported.
                Funding/Support: The study was supported by the Department of Veterans Affairs, Office of Research and Development (HSR&D grants C19 21-278 to Drs Ioannou, Bohnert, Boyko, and Maciejewski and C19 21-279 to Drs O’Hare, Bowling, Iwashyna, Hynes, and Viglianti and RCS 10-391 to Dr Maciejewski).
                Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
                Disclaimer: The contents do not represent the views of the US Department of Veterans Affairs or the US Government.
                Article
                zoi220685
                10.1001/jamanetworkopen.2022.24359
                9338411
                35904783
                5ae314d0-0614-4690-8c11-2a4908fbb160
                Copyright 2022 Ioannou GN et al. JAMA Network Open.

                This is an open access article distributed under the terms of the CC-BY License.

                History
                : 23 March 2022
                : 13 June 2022
                Categories
                Research
                Original Investigation
                Online Only
                Infectious Diseases

                Comments

                Comment on this article